{
    "EVIDENCE": {
        "id": 8351,
        "name": "EID8351",
        "description": "A 62-year-old female patient (AML5) was refractory to conventional chemotherapy and developed disease progression to quizartinib due to a D835I mutation. Using MTT to measure cytotoxicity, gilteritinib inhibited this patient\u2019s relapse sample. Additionally, immunoblot demonstrated gilteritinib inhibited FLT3 phosphoryaltion at a concentration of 20 nM in the patient dereivd relapse cells.",
        "disease": {
            "id": 3,
            "name": "Acute Myeloid Leukemia",
            "display_name": "Acute Myeloid Leukemia",
            "doid": "9119",
            "url": "http://www.disease-ontology.org/?id=DOID:9119"
        },
        "drugs": [
            {
                "id": 641,
                "name": "Gilteritinib",
                "ncit_id": "C116722",
                "aliases": [
                    "Xospata",
                    "ASP2215",
                    "ASP-2215",
                    "6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide"
                ]
            }
        ],
        "rating": 2,
        "evidence_level": "D",
        "evidence_type": "Predictive",
        "clinical_significance": "Sensitivity/Response",
        "evidence_direction": "Supports",
        "variant_origin": "Somatic",
        "drug_interaction_type": null,
        "status": "accepted",
        "type": "evidence",
        "source": {
            "id": 3336,
            "name": "Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.",
            "citation": "Lee et al., 2017, Blood",
            "citation_id": "27908881",
            "source_type": "PubMed",
            "asco_abstract_id": null,
            "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/27908881",
            "open_access": true,
            "pmc_id": "PMC5234222",
            "publication_date": {
                "year": 2017,
                "day": 12
            },
            "journal": "Blood",
            "full_journal_title": "Blood",
            "status": "partially curated",
            "is_review": false,
            "clinical_trials": []
        },
        "variant_id": 3075,
        "phenotypes": [],
        "assertions": [
            {
                "id": 33,
                "type": "assertion",
                "name": "AID33",
                "summary": "FLT3 tyrosine kinase domain mutations at residue D835 in relapsed / refractory acute myeloid leukemia (AML) are sensitive to Gilteritinib, a Type I FLT3 inhibitor.",
                "description": "Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are the most common mutations in acute myeloid leukemia (AML). 5 to 10% of AML is associated with activating point mutations in the FLT3 tyrosine kinase domain (TKD), particularly at the residue D835. FLT3 TKD mutations at the D835 residue are a commonly reported mechanism of clinical resistance to type II FLT3 inhibitors (sorafenib, quizartinib and ponatinib), which bind only the inactive kinase conformation. However, Gilteritinib, an oral inhibitor of FLT3 and AXL demonstrated preclinical activity against type II FLT3 inhibitor resistance-conferring D835 mutations and clinical activity as monotherapy in Relapsed/Refractory (R/R) FLT3-mutated AML. In the phase 1/2 CHRYSALIS clinical trial (Perl AE, et al., 2017), Gilteritinib demonstrated significant single-agent activity in R/R AML with FLT3 ITD, D835, I836 mutations, achieving an overall response rate of 40%. A randomized phase 3 study of Gilteritinib (ADMIRAL trial, NCT02421939) compared with salvage chemotherapy in AML demonstrated a significant overall survival benefit in the gilteritinib arm (9.3 months) compared with chemotherapy (5.6 months). Event-free survival in the gilteritinib arm was also superior (Perl AE, et al., 2019). Based on findings from this study, the US Food and Drug Administration (FDA) approved Gilteritinib as the first FLT3 inhibitor indicated for use as monotherapy R/R AML with FLT3 ITD mutations or TKD D835 or I836 mutations.",
                "gene": {
                    "name": "FLT3",
                    "id": 24
                },
                "variant": {
                    "name": "D835",
                    "id": 437
                },
                "disease": {
                    "id": 3,
                    "name": "Acute Myeloid Leukemia",
                    "display_name": "Acute Myeloid Leukemia",
                    "doid": "9119",
                    "url": "http://www.disease-ontology.org/?id=DOID:9119"
                },
                "drugs": [
                    {
                        "id": 641,
                        "name": "Gilteritinib",
                        "ncit_id": "C116722",
                        "aliases": [
                            "Xospata",
                            "ASP2215",
                            "ASP-2215",
                            "6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide"
                        ]
                    }
                ],
                "evidence_type": "Predictive",
                "evidence_direction": "Supports",
                "clinical_significance": "Sensitivity/Response",
                "fda_regulatory_approval": true,
                "status": "submitted"
            }
        ],
        "gene_id": 24
    },
    "GENE": {
        "id": 24,
        "name": "FLT3",
        "entrez_id": 2322,
        "description": "FLT3 is an important cytokine receptor involved in normal hematopoiesis. Mutations in this gene are common in acute myeloid leukemia (AML) and screening for mutations in this gene has been recommended by the World Health Organization in patients with AML, particularly in cases of cytogenetically normal AML (CN-AML). FLT3 mutations commonly co-occur with mutations such as NPM1 that are associated with CN-AML and likely modulate prognostic impact. While FLT3-ITD mutations have been associated with poorer prognosis in AML, the prognostic impact of FLT3-TKD mutations are still up for debate.",
        "variants": [
            {
                "name": "F691L",
                "id": 3071,
                "evidence_items": {
                    "accepted_count": 2,
                    "rejected_count": 0,
                    "submitted_count": 7
                }
            },
            {
                "name": "D835",
                "id": 437,
                "evidence_items": {
                    "accepted_count": 4,
                    "rejected_count": 1,
                    "submitted_count": 4
                }
            },
            {
                "name": "TKD MUTATION",
                "id": 56,
                "evidence_items": {
                    "accepted_count": 7,
                    "rejected_count": 0,
                    "submitted_count": 0
                }
            },
            {
                "name": "OVEREXPRESSION",
                "id": 603,
                "evidence_items": {
                    "accepted_count": 1,
                    "rejected_count": 0,
                    "submitted_count": 0
                }
            },
            {
                "name": "D835I",
                "id": 3075,
                "evidence_items": {
                    "accepted_count": 1,
                    "rejected_count": 0,
                    "submitted_count": 0
                }
            },
            {
                "name": "ITD D651G",
                "id": 3219,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "ITD & Y842C",
                "id": 3210,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 2
                }
            },
            {
                "name": "E611_F612INS25",
                "id": 1544,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 2
                }
            },
            {
                "name": "G697R",
                "id": 2817,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "D835 & I836",
                "id": 3231,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "MUTATION",
                "id": 519,
                "evidence_items": {
                    "accepted_count": 4,
                    "rejected_count": 0,
                    "submitted_count": 4
                }
            },
            {
                "name": "ITD",
                "id": 55,
                "evidence_items": {
                    "accepted_count": 29,
                    "rejected_count": 2,
                    "submitted_count": 5
                }
            },
            {
                "name": "D835Y",
                "id": 3011,
                "evidence_items": {
                    "accepted_count": 2,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "N676K",
                "id": 3053,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "D835E",
                "id": 1397,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "N841K",
                "id": 3213,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "M664I",
                "id": 3165,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "Y693",
                "id": 3055,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "Y842C",
                "id": 3070,
                "evidence_items": {
                    "accepted_count": 5,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "V592_D593INSDFREY",
                "id": 1632,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 4
                }
            },
            {
                "name": "ITD & TKD MUTATIONS",
                "id": 3118,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 2
                }
            },
            {
                "name": "ITD & D835(V/Y/F/H)",
                "id": 3209,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "I836",
                "id": 3232,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "Y591_V592INSVDFREYE",
                "id": 1630,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 4
                }
            },
            {
                "name": "N841I",
                "id": 3201,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "ITD and co-mutations",
                "id": 3218,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 1,
                    "submitted_count": 0
                }
            },
            {
                "name": "ITD & D839G",
                "id": 3211,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 2
                }
            },
            {
                "name": "G697S",
                "id": 3212,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "ITD I687F",
                "id": 3221,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "AMPLIFICATION",
                "id": 2619,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 2
                }
            },
            {
                "name": "ITD&F691(I/L)",
                "id": 3208,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "D839N",
                "id": 3168,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "ITD N676K",
                "id": 2785,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "ITD  N676D",
                "id": 3220,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "Y842H",
                "id": 3234,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "T227M",
                "id": 540,
                "evidence_items": {
                    "accepted_count": 1,
                    "rejected_count": 0,
                    "submitted_count": 0
                }
            },
            {
                "name": "E588_Y589INSKYFYVDFRE",
                "id": 1631,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 4
                }
            },
            {
                "name": "D839G",
                "id": 3160,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 4
                }
            },
            {
                "name": "Y589D",
                "id": 3233,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "D835H/Y",
                "id": 613,
                "evidence_items": {
                    "accepted_count": 1,
                    "rejected_count": 0,
                    "submitted_count": 0
                }
            },
            {
                "name": "K663Q",
                "id": 3166,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "D839H",
                "id": 3169,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "D839A",
                "id": 3167,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "D835V",
                "id": 1302,
                "evidence_items": {
                    "accepted_count": 7,
                    "rejected_count": 0,
                    "submitted_count": 6
                }
            },
            {
                "name": "D835H",
                "id": 612,
                "evidence_items": {
                    "accepted_count": 1,
                    "rejected_count": 0,
                    "submitted_count": 3
                }
            }
        ],
        "aliases": [
            "FLT3",
            "STK1",
            "FLK2",
            "FLK-2",
            "CD135"
        ],
        "type": "gene"
    },
    "VARIANT": {
        "id": 3075,
        "entrez_name": "FLT3",
        "entrez_id": 2322,
        "name": "D835I",
        "description": "",
        "gene_id": 24,
        "type": "variant",
        "variant_types": [],
        "civic_actionability_score": 0,
        "coordinates": {
            "chromosome": null,
            "start": null,
            "stop": null,
            "reference_bases": null,
            "variant_bases": null,
            "representative_transcript": null,
            "chromosome2": null,
            "start2": null,
            "stop2": null,
            "representative_transcript2": null,
            "ensembl_version": null,
            "reference_build": null
        },
        "evidence_items": [
            {
                "id": 8351,
                "name": "EID8351",
                "description": "A 62-year-old female patient (AML5) was refractory to conventional chemotherapy and developed disease progression to quizartinib due to a D835I mutation. Using MTT to measure cytotoxicity, gilteritinib inhibited this patient\u2019s relapse sample. Additionally, immunoblot demonstrated gilteritinib inhibited FLT3 phosphoryaltion at a concentration of 20 nM in the patient dereivd relapse cells.",
                "disease": {
                    "id": 3,
                    "name": "Acute Myeloid Leukemia",
                    "display_name": "Acute Myeloid Leukemia",
                    "doid": "9119",
                    "url": "http://www.disease-ontology.org/?id=DOID:9119"
                },
                "drugs": [
                    {
                        "id": 641,
                        "name": "Gilteritinib",
                        "ncit_id": "C116722",
                        "aliases": [
                            "Xospata",
                            "ASP2215",
                            "ASP-2215",
                            "6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide"
                        ]
                    }
                ],
                "rating": 2,
                "evidence_level": "D",
                "evidence_type": "Predictive",
                "clinical_significance": "Sensitivity/Response",
                "evidence_direction": "Supports",
                "variant_origin": "Somatic",
                "drug_interaction_type": null,
                "status": "accepted",
                "type": "evidence",
                "source": {
                    "id": 3336,
                    "name": "Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.",
                    "citation": "Lee et al., 2017, Blood",
                    "citation_id": "27908881",
                    "source_type": "PubMed",
                    "asco_abstract_id": null,
                    "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/27908881",
                    "open_access": true,
                    "pmc_id": "PMC5234222",
                    "publication_date": {
                        "year": 2017,
                        "day": 12
                    },
                    "journal": "Blood",
                    "full_journal_title": "Blood",
                    "status": "partially curated",
                    "is_review": false,
                    "clinical_trials": []
                },
                "variant_id": 3075,
                "phenotypes": []
            }
        ],
        "variant_groups": [],
        "assertions": [],
        "variant_aliases": [],
        "hgvs_expressions": [],
        "clinvar_entries": [],
        "allele_registry_id": null
    },
    "ASSERTIONS": [
        {
            "id": 33,
            "type": "assertion",
            "name": "AID33",
            "summary": "FLT3 tyrosine kinase domain mutations at residue D835 in relapsed / refractory acute myeloid leukemia (AML) are sensitive to Gilteritinib, a Type I FLT3 inhibitor.",
            "description": "Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are the most common mutations in acute myeloid leukemia (AML). 5 to 10% of AML is associated with activating point mutations in the FLT3 tyrosine kinase domain (TKD), particularly at the residue D835. FLT3 TKD mutations at the D835 residue are a commonly reported mechanism of clinical resistance to type II FLT3 inhibitors (sorafenib, quizartinib and ponatinib), which bind only the inactive kinase conformation. However, Gilteritinib, an oral inhibitor of FLT3 and AXL demonstrated preclinical activity against type II FLT3 inhibitor resistance-conferring D835 mutations and clinical activity as monotherapy in Relapsed/Refractory (R/R) FLT3-mutated AML. In the phase 1/2 CHRYSALIS clinical trial (Perl AE, et al., 2017), Gilteritinib demonstrated significant single-agent activity in R/R AML with FLT3 ITD, D835, I836 mutations, achieving an overall response rate of 40%. A randomized phase 3 study of Gilteritinib (ADMIRAL trial, NCT02421939) compared with salvage chemotherapy in AML demonstrated a significant overall survival benefit in the gilteritinib arm (9.3 months) compared with chemotherapy (5.6 months). Event-free survival in the gilteritinib arm was also superior (Perl AE, et al., 2019). Based on findings from this study, the US Food and Drug Administration (FDA) approved Gilteritinib as the first FLT3 inhibitor indicated for use as monotherapy R/R AML with FLT3 ITD mutations or TKD D835 or I836 mutations.",
            "gene": {
                "name": "FLT3",
                "id": 24
            },
            "variant": {
                "name": "D835",
                "id": 437
            },
            "disease": {
                "id": 3,
                "name": "Acute Myeloid Leukemia",
                "display_name": "Acute Myeloid Leukemia",
                "doid": "9119",
                "url": "http://www.disease-ontology.org/?id=DOID:9119"
            },
            "drugs": [
                {
                    "id": 641,
                    "name": "Gilteritinib",
                    "ncit_id": "C116722",
                    "aliases": [
                        "Xospata",
                        "ASP2215",
                        "ASP-2215",
                        "6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide"
                    ]
                }
            ],
            "evidence_type": "Predictive",
            "evidence_direction": "Supports",
            "clinical_significance": "Sensitivity/Response",
            "fda_regulatory_approval": true,
            "status": "submitted"
        }
    ]
}